Last reviewed · How we verify
Talzenna (talazoparib-tosylate)
Talazoparib inhibits PARP enzymes, causing DNA damage and cell death in cancer cells with DNA repair defects.
At a glance
| Generic name | talazoparib-tosylate |
|---|---|
| Sponsor | Pfizer |
| Drug class | Poly(ADP-Ribose) Polymerase Inhibitor |
| Target | PARP1, PARP2 |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2018 |
| Annual revenue | 182 |
Mechanism of action
Talazoparib works by blocking PARP enzymes, which are important for repairing damaged DNA. When these enzymes are inhibited, cancer cells with existing DNA repair issues, such as mutations in BRCA1 or BRCA2, accumulate more DNA damage, leading to reduced cell growth and cell death.
Approved indications
- Germline BRCA-mutated, HER2-negative metastatic breast cancer
Common side effects
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Headache
- Alopecia
- Decreased appetite
Drug interactions
- Itraconazole
- Amiodarone
- Carvedilol
- Clarithromycin
- Verapamil
- Enzalutamide
- BCRP Inhibitors
Key clinical trials
- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (PHASE3)
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial (PHASE1)
- Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer (PHASE1)
- Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer (PHASE2)
- Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer (PHASE2)
- Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) (PHASE2)
- Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Talzenna CI brief — competitive landscape report
- Talzenna updates RSS · CI watch RSS
- Pfizer portfolio CI